#United States #San Francisco #Nektar Therapeutics #Rezpegaldesleukin #EADV Congress

Nektar Therapeutics Announces Presentations at EADV Congress 2026

Nektar Therapeutics (Nasdaq: NKTR) has recently announced its upcoming participation in the European Academy of Dermatology and Venereology (EADV) Congress, set to take place in Vienna, Austria from September 30 to October 3, 2026. The company will be presenting findings from its Phase 2b studies regarding rezpegaldesleukin, a potential treatment for atopic dermatitis and alopecia areata.

Key Presentations

Nektar will offer three separate oral presentations, highlighting critical data from the REZOLVE-AA study focusing on patients with alopecia areata. Notably, this includes six-month off-treatment data that evaluates the durability of responses in participants, measured using the Severity of Alopecia Tool (SALT). Furthermore, the congress will feature previously reported maintenance data from the REZOLVE-AD study, which examines patients diagnosed with atopic dermatitis. Additionally, a late-breaking presentation will showcase new insights from a biomarker sub-study about rezpegaldesleukin conducted at the Icahn School of Medicine at Mount Sinai.

Presentation Details

The presentations scheduled for EADV are:
1. “Rezpegaldesleukin, a Novel Regulatory T Cell-Inducing Biologic, Demonstrates Efficacy and Safety in Severe-to-Very-Severe Alopecia Areata 52-Week Results from the Phase 2b REZOLVE-AA Study”
- Presenter: Dr. David Rosmarin, M.D., from Indiana University School of Medicine.
- Session: FC04.1D
- Date/Time: Thursday, October 1st, 2026, 16:30–16:40 CET
- Location: Hall N
- Abstract No: AS-1872

2. “Rezpegaldesleukin Provides Durable and Deepening Improvements in the Signs and Symptoms of Atopic Dermatitis with Monthly and Quarterly Dosing Results from the Phase 2b REZOLVE-AD Maintenance Part of Study”
- Presenter: Dr. Thomas Bieber, M.D., Ph.D.
- Session: FC02.1B
- Date/Time: Thursday, October 1st, 2026, 10:25–10:35 CET
- Location: Hall N
- Abstract No: AS-1732

3. “Multi-omic profiling identifies early molecular responses to rezpegaldesleukin, a novel regulatory T cell-inducing therapy, in atopic dermatitis”
- Presenter: Dr. Emma Guttman-Yassky, M.D., Ph.D., from Icahn School of Medicine at Mount Sinai.
- Session: D1T01.2
- Date/Time: Wednesday, September 30th, 2026, 16:30–16:45 CET
- Location: Hall A
- Abstract No: LB-219

Investor Conference Call

In conjunction with these presentations, Nektar will host a conference call for investors and analysts on October 1, 2026, at 8:00 AM ET/2:00 PM CET. The call will delve into the new six-month off-treatment data from the REZOLVE-AA study. Dr. Benjamin Ungar, a leading figure at the Alopecia Center of Excellence, will also join the discussion. Those interested can access the live webcast through a dedicated link on Nektar's investor relations site.

About Rezpegaldesleukin

Rezpegaldesleukin is emerging as a leading candidate aimed at addressing the immune system's imbalance in various autoimmune and inflammatory disorders by targeting the interleukin-2 receptor complex. This innovative therapy could potentially redefine treatment paradigms for patients suffering from atopic dermatitis and alopecia areata, with the FDA having granted Fast Track designations for both conditions. Its development marks a crucial step for Nektar Therapeutics, as it plays a vital role in the company's mission to synthesize effective treatments for these challenging health issues.

Conclusion

The EADV Congress 2026 is poised to be a significant event for Nektar Therapeutics, as they present crucial data that could potentially pave the way for new treatment options for patients with severe skin conditions. The outcomes of these studies will be critical as healthcare professionals continue to explore innovative approaches in managing debilitating diseases like alopecia areata and atopic dermatitis.